[Effects of combined treatment with rosiglitazone and intermediate-acting insulin on carbohydrate metabolism in patients with type 2 diabetes mellitus].
OBJECTIVE
To study efficacy and safety of rosiglitazone + NPH insulin combined treatment in patients with type 2 diabetes mellitus (DM).


METHODS
The trial included 43 patients with DM aged 44-75 on NPH insulin. The patients were divided into two groups. The study group received NPH insulin + a single morning dose of 4 mg/day rosiglitazone, the control group received NPH insulin only. The treatment lasted 24 weeks.


RESULTS
24-week therapy in the study group lowered HbA(1c) from 8.16 +/- 0.23 to 6.82 +/- 0.18% (p<0.05), fasting glycemia--from 9.68 +/- 0.48 to 6.4 +/- 0.32 mmol/l, postprandial glycemia--from 12.3 +/- 0.44 to 8.4 +/- 0.56 mmol/l, HOMA-IR index--from 7.65 +/- 1.12 to 4.26 +/- 0.59. In group 2 HbAlc--from 7.84 +/- 0.15 to 7.49 +/- 0.17 (p<0.05), from 9.21 +/- 0.65 to 8.38 +/- 0.50 mmol/l, 11.92 +/- 0.53 to 9.97 +/- 0.45 mmol/l, 6.77 +/- 0.79 to 5.73 +/- 0.63. The combined treatment produced positive changes in lipid metabolism: total cholesterol decreased from 6.37 +/- 0.36 to 5.67 +/- 0.32 mmol/l (p<0.005), TG--from 2.46 +/- 0.64 mmol/l to 1.82 +/- 0.46 mmol/l (p<0.005), LDLP--from 3.99 +/- 0.40 to 3.58 +/- 0.37 mmol/l. Need in insulin diminished by 10%.


CONCLUSIONS
Treatment results showed that administration of rosiglitazone in combination with NPH insulin has a good safety and tolerance profile in type 2 DMp atients.
Kandalintseva
O A
OA
Ametov
A S
AS
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D050260:Carbohydrate Metabolism / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007336:Insulin, Isophane / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008055:Lipids; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D007336:Insulin, Isophane